Human leukocyte antigen g donor-recipient matching of the 14-bp polymorphism protects against cancer following heart transplant

Background: Following transplant, cancer is a leading cause of morbidity and mortality. Human leukocyte antigen-G (HLA-G) – an immune checkpoint molecule – reduces allograft rejection by dampening host immune responses. Reports suggest malignant cells utilize HLA-G to evade the immune system and promote cancer development. Our objective was to evaluate HLA-G donor-recipient polymorphism matching and development of cancer following heart transplant. Methods: Recipients (n=251) and corresponding donors (n=196) were genotyped retrospectively to identify HLA-G polymorphisms in the 5’regulatory (–725, –201), 3’untranslated (+3197, +3187, +3142, 14-bp indel) and coding regions (haplotypes I-VI).
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Clinical Science Source Type: research

Related Links:

Purpose of review In this article, an overview of the survival after lung transplantation will be given, with a focus on factors affecting outcome and differences in survival determined by underlying disease. Recent findings Lung transplantation is an established treatment modality for patients with various end-stage lung diseases. The most recent International Society for Heart and Lung Transplantation Registry reports a 1 and 5-year survival of 85 and 59%, respectively, for adult lung transplant recipients transplanted since 2010. Over the past decades, significant improvements in patient outcomes have been achieved...
Source: Current Opinion in Organ Transplantation - Category: Surgery Tags: LUNG TRANSPLANTATION: Edited by Jasleen Kukreja Source Type: research
After a transplant, cancer is a leading cause of morbidity and mortality. Human leukocyte antigen-G (HLA-G) —an immune checkpoint molecule—reduces allograft rejection by dampening host immune responses. Reports suggest malignant cells utilize HLA-G to evade the immune system and promote cancer development. Our objective was to evaluate HLA-G donor-recipient polymorphism matching and development of can cer after a heart transplant.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: ORIGINAL CLINICAL SCIENCE Source Type: research
Polyfunctional T cells (PTC) have the ability to secrete ≥2 cytokines per cell when stimulated and increased presence of PTC is associated with favorable outcomes in patients undergoing chimeric antigen receptor (CAR) T cell therapy for cancer. In pediatric heart transplant recipients (PHT), the development of PTC may represent increased exposure to don or specific antigens with the potential to induce greater allograft damage through elevated cytokine production; however, the ability of circulating PTC to predict acute cellular rejection (ACR) in PHT is unknown.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (535) Source Type: research
This study was undertaken to identify risk factors using the UNOS database.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (294) Source Type: research
In conclusion, circulating MDSCs are measurable, functional and have a G-MDSC phenotype in lung transplant patients. Their frequency is increased in stable patients, decreased during post-transplant complications, and related to level of immunosuppression. This study may pave the way for further investigations of MDSC in the context of lung transplantation. Introduction From a transplant immunological point of view, graft acceptance is the fundamental element in allograft survival. Graft acceptance is realized by blocking the immune system with immunosuppression preventing host immune cells to recognized and attack...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Qiancheng Deng1, Yangyang Luo1,2, Christopher Chang3, Haijing Wu1, Yan Ding4* and Rong Xiao1* 1Hunan Key Laboratory of Medical Epigenetics, Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, China 2Department of Dermatology, Hunan Children's Hospital, Changsha, China 3Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, Davis, CA, United States 4Department of Dermatology, Hainan Provincial Dermatology Disease Hospital, Haikou, China Autoimmune diseases are usually complex and multifactorial, characterized by aberrant produc...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusion: Mesenchymal stem cell transplantation could be use as a potential treatment for PHLF. Introduction Partial hepatectomy is an important treatment for benign and malignant liver diseases. Although the liver can be completely regenerated after partial excision or injury, at least 1/3 of the liver should be retained in most of the patients, and 40–50% should be retained in patients with parenchymal liver disease (Adams et al., 2013; Cieslak et al., 2014). Postoperative complications, such as acute post-hepatectomy liver failure (PHLF) or small liver syndrome, may occur when the scope of excision is to...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Post-transplant malignancy (PTM) is a major cause of morbidity and mortality following transplantation. Human leukocyte antigen G (HLA-G) is an immune checkpoint molecule that reduces allograft rejection by dampening the host immune response. Reports suggest HLA-G may be utilized by malignant cells to evade the immune system and promote cancer development. Our objective was to evaluate HLA-G donor/recipient genotype matching and development of PTM following heart transplantation.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: 330 Source Type: research
Myeloid-derived suppressor cells (MDSC) are a heterogeneous group of immune cells of the myeloid lineage. MDSC expand in pathological situations such as chronic infections, cancer and transplant rejection; and suppress T-cell responses. Chronic lung allograft dysfunction (CLAD) is the single most important factor limiting long-term survival after lung transplantation (LTx), MDSCs may also play a role in its complex pathophysiology. We investigated the technical feasibility of quantifying granulocytic/polymorphonuclear MDSCs (G/PMN-MDSC) in peripheral blood from LTx recipients and secondly, assessed MDSC in post-transplant ...
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: 626 Source Type: research
We have read with great interest the case report by Pujol et al entitled Synchronous multiple non-small cell lung cancers in an allograft lung recipient [1], about a young cystic fibrosis lung transplant recipient who developed metastatic lung cancer. We would like to comment on this ‘rare’ long-term complication post lung transplantation. Recent registry data from the International Society of Heart and Lung Transplantation showed that the overall incidence of a malignancy post lung transplantation at 1, 5 and 10 years is 5.3%, 19.6% and 31.7% respectively [2] In observation al studies the incidence of lung can...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Bone Graft | Cancer | Cancer & Oncology | Cardiology | Heart | Heart Transplant | Lung Transplant | Science | Transplant Surgery | Transplants